Scientists discover antibody that 'neutralizes' virus that causes coronavirus

  • Scientists discover antibody that 'neutralizes' virus that causes coronavirus

Scientists discover antibody that 'neutralizes' virus that causes coronavirus

The antibody can be administered both orally and intravenously.

These are man-made antibodies that act like human antibodies in the immune system. The drug also reportedly does not bind to human cells, which suggests it will not have negative side-effects in people.

Can Be A Preventive Measure As Well?

Peter Horby, professor of emerging infectious diseases and global health at the University of Oxford and chief investigator of the trial, said: "We have already discovered that one treatment, dexamethasone, benefits Covid-19 patients, but the death rate remains too high so we must keep searching for others".

One of the world's largest efforts to find effective COVID-19 treatments will evaluate the impact of REGN-COV2, an investigational antibody cocktail, on mortality, hospital stays, and the need for ventilation. Xianglei Liu of Pitt is also co-lead author.

How does it do it?

The discovery links to an immunoglobin antibody in the blood.

The cocktail of drugs targets two components in the spike protein of the Covid-19 virus with the aim of interrupting its ability to infect.

When the VH component of an antibody fuses with the tail region of the immunoglobulin, the drug Ab8 produced.

The researchers said that the medicine could be administered as an inhaled drug or intradermally because of its small size.

Its small size might allow it to be given as an inhaled drug or intradermally, rather than intravenously through an IV drip, like most monoclonal antibodies now in development.

UPMC and University of Pittsburgh medical researchers announced a "scientific breakthrough" in a Tuesday afternoon news conference that may provide the key to fighting COVID-19.

"The idea is that the antibody will block the spread of the virus throughout the body". The isolated part is found useful in constructing a drug Ab8 to treat the affected patients.

At very low concentrations, Ab8 completely blocked the virus from entering cells. The SARS-CoV-2 virus is taken as bait for the research. In mice trials, those treated with Ab8 had 10-fold less of the amount of infectious virus compared to those that were untreated.

Ab8 also was effective in treating and preventing SARS-CoV-2 infection in hamsters, as evaluated by scientists the University of Saskatchewan. This also better neutralizes the virus.

Mellors says, "The COVID-19 pandemic is a global challenge facing humanity, but biomedical science and human ingenuity are likely to overcome it..."

REGN-COV2, which was created by the U.S. firm Regeneron, is made up of two monoclonal antibodies (REGN10933 and REGN10987).

Funds for the research comes from the National Institutes of Health grants, and UPMC, the Burroughs Wellcome Fund.